0001493152-21-002062.txt : 20210129 0001493152-21-002062.hdr.sgml : 20210129 20210129090022 ACCESSION NUMBER: 0001493152-21-002062 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210129 DATE AS OF CHANGE: 20210129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vitality Biopharma, Inc. CENTRAL INDEX KEY: 0001438943 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 753268988 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53832 FILM NUMBER: 21568346 BUSINESS ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 530-231-7800 MAIL ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: Stevia First Corp. DATE OF NAME CHANGE: 20111020 FORMER COMPANY: FORMER CONFORMED NAME: Legend Mining Inc. DATE OF NAME CHANGE: 20080630 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020

[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-53832

VITALITY BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada

75-3268988

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1901 Avenue of the Stars, 2^nd Floor
Los Angeles, CA		90067
(Address of principal executive offices)		(Zip Code)

(530) 231-7800

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol		*Name of each exchange on which registered:**
Common Stock		VBIO		-

*The Company’s common stock trades with limited liquidity on the grey market. Grey market stocks are not traded or quoted on an exchange or inter-dealer quotation system, but are reported by broker-dealers to their self-regulatory organization who, in turn, distribute the trade data to market data vendors and financial websites.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [X]	Smaller reporting company [X]
	Emerging growth company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

As of January 28, 2021, there were 50,840,147 shares of the registrant’s common stock outstanding.

VITALITY BIOPHARMA, INC.

Quarterly Report on Form 10-Q

For the Quarterly Period Ended

December 31, 2020

INDEX

PART I - FINANCIAL INFORMATION	3

Item 1. Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	20
Item 4. Controls and Procedures	20

PART II - OTHER INFORMATION	21

Item 1. Legal Proceedings	21
Item 1A. Risk Factors	21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 6. Exhibits	22

SIGNATURES	23

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

VITALITY BIOPHARMA, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019

(Unaudited)

CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS	4

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS	5

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY	6

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS	7

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS	8

VITALITY BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2020			March 31, 2020
		(unaudited)
Assets

Current Assets
Cash and cash equivalents	$	1,441,471		$	2,392,225
Prepaid expenses and other current assets		13,195			15,666
Total current assets		1,454,666			2,407,891
Deposits		26,157			35,752
Operating lease right-of-use asset		22,817			123,606

Total Assets	$	1,503,640		$	2,567,249

Liabilities and Stockholders’ Equity

Current Liabilities
Accounts payable and accrued liabilities	$	72,078		$	862,528
Advance		296,653			296,653
Operating lease liability, short-term		23,194			125,679
Total current liabilities		391,925			1,284,860

Total liabilities		391,925			1,284,860

Commitments and contingencies		-			-

Stockholders’ Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 50,840,147 shares issued and outstanding		50,640			50,640
Additional paid-in-capital		48,128,153			47,778,607
Accumulated deficit		(47,067,078	)		(46,546,858	)
Total stockholders’ equity		1,111,715			1,282,389
Total Liabilities and Stockholders’ Equity	$	1,503,640		$	2,567,249

See accompanying notes to the condensed consolidated financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended December 31,						Nine Months Ended December 31,
	2020			2019			2020			2019
Revenues	$	-		$	-		$	-		$	-

Operating expenses:
General and administrative		394,567			506,926			1,342,110			2,094,026
Research and development		71,975			241,840			338,268			864,849
Total operating expenses		466,542			748,766			1,680,378			2,958,875

Loss from operations		(466,542	)		(748,766	)		(1,680,378	)		(2,958,875	)

Other income (expense)
Change in fair value of derivative liability		-			1,711			-			35,625
Gain on extinguishment of note payable		97,516			-			97,516			-
Gain on settlement		1,062,405			-			1,062,405			-
Other		(429	)		529			237			24,053
Total other income (expense), net		1,159,492			2,240			1,160,158			59,678

Income (loss) from continuing operations		692,950			(746,526	)		(520,220	)		(2,899,197	)

Loss from discontinued operations		-			(48,769	)		-			(714,827	)

Net income (loss)	$	692,950		$	(795,295	)	$	(520,220	)	$	(3,614,024	)

Net income (loss) per common share
Income (loss) from continuing operations	$	0.01		$	(0.01	)	$	(0.01	)	$	(0.06	)
Loss from discontinued operations	$	-		$	(0.00	)	$	-		$	(0.01	)

Weighted average number of common shares outstanding
Basic and diluted		50,840,147			50,840,147			50,840,147			51,773,420

See accompanying notes to the condensed consolidated financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

THREE AND NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019

	Three months ended December 31, 2020 (Unaudited)
	Common Stock				Additional
	Number of shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance – September 30, 2020		50,840,147	$	50,640	$	48,015,844	$	(47,760,028	)	$	306,456
Fair value of vested stock options		-		-		112,309		-			112,309
Net income		-		-		-		692,950			692,950
Balance as of December 31, 2020 (Unaudited)		50,840,147	$	50,640	$	48,128,153	$	(47,067,078	)	$	1,111,715

	Three months ended December 31, 2019 (Unaudited)
	Common Stock				Additional
	Number of shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance as of September 30, 2019		50,840,147	$	50,640	$	47,502,211	$	(45,000,232	)	$	2,552,619
Fair value of vested stock options		-		-		142,282		-			142,282
Net loss		-		-		-		(795,295	)		(795,295	)
Balance as of December 31, 2019 (Unaudited)		50,840,147	$	50,640	$	47,644,493	$	(45,795,527	)	$	1,899,606

	Nine months ended December 31, 2020 (Unaudited)
	Common Stock				Additional
	Number of shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance – March 31, 2020		50,840,147	$	50,640	$	47,778,607	$	(46,546,858	)	$	1,282,389
Fair value of vested stock options		-		-		349,546		-			349,546
Net loss		-		-		-		(520,220	)		(520,220	)
Balance as of December 31, 2020 (Unaudited)		50,840,147	$	50,640	$	48,128,153	$	(47,067,078	)	$	1,111,715

	Nine months ended December 31, 2019 (Unaudited)
	Common Stock						Additional
	Number of shares			Amount			Paid-in Capital		Accumulated Deficit			Total
Balance as of March 31, 2019		52,290,147		$	52,090		$	47,150,489	$	(42,181,503	)	$	5,021,076
Cancellation of shares		(1,450,000	)		(1,450	)		1,450		-			-
Fair value of vested stock options		-			-			492,554		-			492,554
Net loss		-			-			-		(3,614,024	)		(3,614,024	)
Balance as of December 31, 2019 (Unaudited)		50,840,147		$	50,640		$	47,644,493	$	(45,795,527	)	$	1,899,606

See accompanying notes to the condensed consolidated financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended December 31,
	2020			2019

Cash flows from operating activities
Net loss	$	(520,220	)	$	(3,614,024	)
Loss from discontinued operations		-			714,827
Loss from continuing operations		(520,220	)		(2,899,197	)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of vested stock options		349,546			492,554
Operating lease expense		100,789			93,845
Change in fair value of derivative liability		-			(35,625	)
Gain on settlement, net of cash received of $450,000		(612,405	)		-
Gain on extinguishment of note payable		(97,516	)		-
Accrual of interest added to note payable		528			-
Changes in operating assets and liabilities:
Prepaid expense and other current assets		2,471			24,598
Deposits		9,595			(10,000	)
Accounts payable and accrued liabilities		(178,045	)		292,521
Accounts payable - related party		-			(5,200	)
Operating lease liability		(102,485	)		(97,954	)
Net cash used in operating activities- continuing operations		(1,047,742	)		(2,144,458	)
Net cash used in operating activities- discontinued operations		-			(714,883	)

Net cash used in operating activities		(1,047,742	)		(2,859,341	)

Cash flows from financing activities:
Proceeds from note payable		96,988			-
Net cash provided by financing activities		96,988			-

Net decrease in cash		(950,754	)		(2,859,341	)

Cash and cash equivalents - beginning of period		2,392,225			5,982,741
Cash and cash equivalent - end of period	$	1,441,471		$	3,123,400

Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-
Supplemental non-cash investing and financing activities:
Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of new lease accounting standard	$	-		$	248,425
Cancellation of shares	$	-		$	1,450

See accompanying notes to the condensed consolidated financial statements.

VITALITY BIOPHARMA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019

(Unaudited)

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

The Company is engaged in the research and development of cannabinoid prodrug pharmaceuticals, which we refer to as cannabosides. We discovered these cannabosides through application of the Company’s proprietary enzymatic bioprocessing technologies. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.

Liquidity

Since we do not have any commercial products currently available in the marketplace, the Company does not generate any revenues. As reflected in the accompanying financial statements, during the nine months ended December 31, 2020, the Company incurred a net loss of $520,220 and used $1,047,742 of cash in our operating activities. As of December 31, 2020, we had $1,441,471 of cash on hand, stockholders’ equity of $1,111,715 and had working capital of $1,062,741.

Our total expenditures for the twelve months following December 31, 2020, are expected to be approximately $1,000,000, which is comprised of research and development and general operating expenses. Based on the funds we had available on December 31, 2020, we believe that we have sufficient capital to fund our anticipated operating expenses for at least one year from the date that the financial statements in this report are issued.

On November 7, 2018, the SEC suspended the trading of our common stock. Our common stock resumed trading with limited liquidity on the grey market on November 21, 2018. Grey market stocks are not traded or quoted on an exchange or inter-dealer quotation system, but are reported by broker-dealers to their self-regulatory organization (“SRO”) and the SRO distributes the trade data to market data vendors and financial websites. Since grey market securities are not traded or quoted on an exchange or inter-dealer quotation system, investor’s bids and offers are not collected in a central spot, so market transparency is diminished and execution of orders is difficult. We are actively pursuing the resumption of ordinary course trading status on the OTCQB.

In September 2020, we retained DelMorgan & Co., an internationally recognized investment banking firm, to advise us on our strategic alternatives, including potential financings, asset divestitures or strategic partnerships. The Company is continuing to work closely with DelMorgan in support of their retention.

While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. We do not have any firm commitments for future capital and until the Company’s securities resume ordinary course trading on the OTCQB (or are listed on a national exchange) it will be difficult to obtain financing on commercially reasonable or acceptable terms. We do not presently have, nor do we expect in the near future to have, material revenue to fund our business from our operations, and we will need to obtain all of our necessary funding from external sources in the near term. Additional financing may be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership may be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Further, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect.

COVID-19 Considerations

The global outbreak of COVID-19 has led to significant disruptions in the global economy, including the curtailment of activities by businesses and consumers in much of the world as governments and others seek to limit the spread of the disease. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures imposed by domestic and foreign governments, the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. In the quarter ended December 31, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. We have also not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.

Basis of Presentation of Unaudited Condensed Financial Information

The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2020 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2020. These financial statements should be read in conjunction with that report.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

Financial Assets and Liabilities Measured at Fair Value

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs:

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts payable, notes payable and advance, approximate their fair values because of the short maturity of these instruments.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Share-Based Payments

The Company periodically issues stock options, warrants, and shares of common stock as share-based compensation to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on FASB ASC 718, Compensation – Stock Compensation (Topic 718) whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

The fair value of the Company’s stock options and warrants are estimated using the Black-Scholes-Merton Option Pricing model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Basic and Diluted Loss Per Share

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

	Nine months ended
	December 31, 2020		December 31, 2019
Options		5,997,544		6,546,710
Warrants		146,668		1,135,003
Total		6,144,212		7,681,713

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates. Research and development costs are expensed as incurred.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning April 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. OPERATING LEASE

At December 31, 2020, the Company’s wholly-owned subsidiary, The Control Center, Inc., (“TCC”) has an operating lease agreement for office space that began in December 2012, and was amended in December 2015 and December 2019, and expires February 28, 2021. In addition, at December 31, 2020, TCC has a sublease agreement in place for the office space that began in September 2019 and expires February 28, 2021. TCC remains the primary obligor on the office space lease agreement. Sublease income was not significant during the three and nine months ended December 31, 2020 and 2019.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its lease as a single lease component. Lease expense is recognized on a straight-line basis over the lease term. An operating lease right-of-use (“ROU”) asset and liability is recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments.

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Nine Months Ended December 31, 2020
Lease Cost
Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed consolidated statement of operations)	$	111,657

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020	$	-
Weighted average remaining lease term – operating leases (in years)		0.2
Average discount rate – operating leases		4.0	%

The supplemental balance sheet information related to leases for the period is as follows:

	At December 31, 2020
Operating leases
Long-term right-of-use asset	$	22,817

Short-term operating lease liability	$	23,194
Total operating lease liabilities	$	23,194

Maturities of the Company’s lease liabilities are as follows (in thousands):

Year Ending March 31	Operating Lease
2021 (remaining 2 months)	$	23,310
Total lease payments		23,310
Less: Imputed interest/present value discount		(116	)
Present value of lease liabilities	$	23,194

Lease expenses were $45,970 and $139,218 during the three and nine months ended December 31, 2020, respectively.

3. GAIN ON EXTINGUISHMENT OF NOTE PAYABLE

On May 6, 2020, the Company was granted a loan (the “PPP” loan) from U.S. Bank for $96,988 pursuant to the Paycheck Protection Program under the CARES Act. The PPP loan bore interest at 1% per annum with the first six months of interest deferred, and was unsecured and guaranteed by the Small Business Administration (the “SBA”). The Company used the entire PPP loan amount for qualifying expenses as described in the CARES Act, including qualifying payroll costs, qualifying group health care benefits, qualifying rent, and qualifying utilities. On November 21, 2020, we received notice that the SBA had reviewed the forgiveness application of our PPP loan and provided forgiveness of our PPP loan of $97,516, including accrued interest of $528. We recognized a gain on extinguishment of the PPP loan of $97,516 during the three and nine months ended December 31, 2020.

4. GAIN ON SETTLEMENT

From 2016 to 2019, the Company recorded approximately $1.1 million due to a vendor for services, of which $612,405 had not been paid and was included in accounts payable at March 31, 2020 and through November 30, 2020. In December 2020, the Company reached a settlement with the vendor to forgive the $612,405 of outstanding invoices, and in addition, the Company received a payment from the vendor of $450,000. This resulted in a gain on settlement of $1,062,405 during the three and nine months ended December 31, 2020.

5. ADVANCE

In July 2018, we received a payment from a third party in the amount of $250,000 and a payment of $46,653 was made on our behalf to a vendor. To date, the Company has not confirmed the nature of these payments. We have recorded these payments as an advance and at December 31, 2020 and March 31, 2020, it is included in current liabilities on the accompanying financial statements.

6. STOCK OPTIONS

A summary of the Company’s stock option activity during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		6,556,710		$	0.89
Granted		-
Exercised		-
Expired		(32,500	)		2.17
Cancelled		(526,666	)		1.42
Balance outstanding at December 31, 2020		5,997,544		$	0.91
Balance exercisable at December 31, 2020		4,622,544		$	0.87

A summary of the Company’s stock options outstanding and exercisable as of December 31, 2020 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, December 31, 2020		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		5,997,544
Options Exercisable, December 31, 2020		375,000	$	0.30	$	0.30
		1,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ $ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		4,622,544

During the nine months ended December 31, 2020, we expensed total stock-based compensation related to stock options of $349,546, and the remaining unamortized cost of the outstanding stock-based awards at December 31, 2020 was approximately $160,000. The remaining unamortized cost will be amortized on a straight-line basis over a weighted average remaining vesting period of one year. At December 31, 2020, the 5,997,044 outstanding stock options had no intrinsic value.

7. WARRANTS

A summary of warrants to purchase the Company’s common stock during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		1,135,003		$	2.19
Granted		-			-
Exercised		-			-
Expired		(988,335	)		2.10
Balance outstanding and exercisable at December 31, 2020		146,668		$	3.00

At December 31, 2020, the 146,668 outstanding stock warrants had no intrinsic value.

8. DISCONTINUED OPERATIONS

In October 2018, the Company acquired Summit Healthtech, Inc. (renamed Vitality Healthtech, Inc.), a specialty healthcare clinic. In addition to Summit Healthcare, the Company sold research diagnostic testing kits (collectively, the Company’s clinical and test kit operations). In May 2019 the Company decided to close its clinical and test kit operations. The clinical and test kit operations meet the discontinued operations criteria and are reported as such in all periods presented on the accompanying condensed consolidated financial statements.

The following table presents the summarized components of loss from discontinued operations for the clinical and test kit operations:

	Three Months Ended December 31,
	2020		2019

Revenue	$	-	$	-

Cost of sales		-		-
Research and development		-		-
General and administrative		-		48,769
Loss from discontinued operations	$	-	$	(48,769	)

	Nine Months Ended December 31,
	2020		2019

Revenue	$	-	$	44,698

Cost of sales		-		143,232
Research and development		-		4,361
General and administrative		-		611,932
Loss from discontinued operations	$	-	$	(714,827	)

9. COMMITMENTS AND CONTINGENCIES

SEC Investigation

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. On May 12, 2020, our outside legal counsel received a letter from the staff of the SEC’s Enforcement Division stating that it has concluded the investigation as to the Company, and that it did not intend to recommend an enforcement action by the SEC against the Company. While certain former officers and directors may request the Company to reimburse them for legal fees related to this matter, at December 31, 2020, management has determined that the Company’s liability for those fees is not probable and we could not reasonably estimate those fees.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this discussion and analysis and elsewhere in this Quarterly Report, the “Company”, “we”, “us” or “our” refer to Vitality Biopharma, Inc., a Nevada corporation.

Cautionary Statement

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Unaudited Condensed Financial Statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 filed on June 29, 2020, and the related audited financial statements and notes included therein.

Certain statements made in this Quarterly Report on Form 10-Q constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include: our ability to continue operating as a going concern; general economic and financial market conditions; our ability to obtain additional financing as necessary; any adverse occurrence with respect to our business or; results of our research and development activities that are less positive than we expect; our ability to bring our intended products to market; market demand for our intended products; shifts in industry capacity; product development or other initiatives by our competitors; fluctuations in the availability of raw materials and costs associated with growing raw materials for our intended products; other factors beyond our control; and the other risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 29, 2020.

Although we believe that the expectations and assumptions reflected in the forward-looking statements we make are reasonable, we cannot guarantee future results, levels of activity or performance. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed by any forward-looking statements. As a result, readers should not place undue reliance on any of the forward-looking statements we make in this report. Forward-looking statements speak only as of the date on which they are made. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Company Overview

Vitality Biopharma is a company focused on the advancement of pharmaceuticals and innovative technologies that improve the lives of patients. We seek to achieve this objective through the development of novel cannabinoid pharmaceutical prodrugs, which we refer to as cannabosides. We conduct our operations using our own personnel and facilities with the support of third-party resources as necessary to advance our drug development programs.

Our cannabinoid-glycoside prodrugs, which we refer to as cannabosides, were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies, that are converted within the body after administration from an inactive molecule into a pharmacologically active drug. Currently, the Company has produced more than 25 novel cannabosides, including glycosylated tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV) and cannabinol (CBN), that are covered by patent applications in the United States and various other countries for composition of matter, method of production and method of use.

Our corporate headquarters is located in Los Angeles, California. As of January 28, 2021, we employed three full-time employees, including one research professional working in our office and laboratory space in Rocklin, California. In the past, we have engaged the services of outside scientific and regulatory consultants to assist in our research and development activities, which is an approach that provides us with flexible and highly-experienced resources to advance our clinical efforts while maintaining a relatively lower overhead cost structure.

Cannaboside Prodrugs

A prodrug is a compound that, after administration, is metabolized into a pharmacologically active drug. Prodrugs are often designed to improve drug properties and reduce known or expected toxicities and adverse side effects. By using our proprietary enzymatic bioprocessing technologies, our clinical research team has developed a novel family of prodrugs by combining cannabinoid and glucose molecules. The resulting compounds, known as cannabosides, have unique commercial applications and patentable compositions of matter, which are separate and distinct from ordinary cannabinoids. The advantages of cannabosides may include: (i) administration in a convenient oral formulation, (ii) targeted delivery with release in the colon or large intestine, (iii) improved stability with limited degradation or drug metabolism, and (iv) delayed release enabling longer-lasting effects and fewer administrations by patients.

Our proprietary glycosylation process, which results in adding one or more glucose molecules to compounds, may enable our new cannabosides to act as prodrugs that achieve targeted delivery of the bioactive compounds of cannabinoids to the gastrointestinal tract. Glycosylated compounds are generally more stable and are water soluble, so upon ingestion, we believe they will remain intact and transit through the esophagus, stomach and upper intestine with limited absorption or degradation from stomach acids. However, once the glycosylated compounds reach the lower intestine, we expect them to encounter glycoside hydrolase enzymes secreted by the human intestinal microbiota that will cleave the polar glucose residues and release the active cannabinoid compound primarily in the large intestine or colon.

We have focused our research and development activities on the glycosylation of cannabinoids given their well-known positive effects on the human endocannabinoid system. Our research and development activities originally focused on the glycosylation of CBD and then later expanded into the glycosylation of THC. The use of the cannabinoid THC has been shown to provide substantial anti-inflammatory benefits on the human body, among other benefits, but is limited as a pharmaceutical option given its psychoactive and intoxicating properties. However, by glycosylating THC, we have learned through initial animal studies that the binding of glucose and THC molecules restricts the release of THC into the body’s digestive system until the prodrug reaches the large intestine, at which point the glycoside hydrolase enzymes cleave the glucose from the prodrug and the THC is released in a targeted and restricted manner. Further, we have learned through our initial animal studies that this targeted release of THC, which could be provided in very low doses to achieve physiologically beneficial results, serves as an anti-inflammatory agent in the lower gastrointestinal tract and minimizes the amount of THC absorbed into the blood stream, thereby avoiding the psychoactive and intoxicating properties that hinder the broader pharmaceutical use of THC.

We are developing our THC-glycoside prodrugs for the treatment of gastrointestinal diseases, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) because of the targeted release described above. IBD is a frequently chronic inflammatory condition where parts of the digestive system become inflamed from an overactive immune response. The disease can lead to irreversible damage to the gastrointestinal tract and may require surgery to remove affected areas of the intestine. Two major forms of the disease are Crohn’s disease, which can affect any part of the digestive system, and ulcerative colitis, which often affects the colon or large intestine. The disease is often unpredictable with periods of painful and debilitating symptoms followed by periods of remission with limited symptoms. IBS has similar symptoms to IBD, including abdominal pain, but the underlying disease process is quite different. IBS is a functional gastrointestinal disorder that commonly affects the large intestine and is characterized by abdominal cramping, diarrhea, constipation, and pain. Currently, patients suffering from IBD are frequently prescribed anti-inflammatory drugs such as steroids, biologics and immunosuppressants, and patients suffering from IBS are prescribed antibiotics, antidepressants and gastrointestinal motility compounds, all of which often result in unwanted side effects.

Our most promising THC-glycoside (VBX-100) is being developed as an oral prodrug for the treatment of IBD and IBS. VBX-100 was selected from our THC-glycoside portfolio due to its compatibility with commercial production techniques and the optimal prodrug delivery profile that maximizes intestinal anti-inflammatory properties while minimizing psychoactive or intoxicating effects. Initial pre-clinical studies on the efficacy of VBX-100 in animal models have shown favorable outcomes, including reduced inflammation of the gastrointestinal tract and no measurable systemic THC found in tissue examined using highly-sensitive testing equipment. Our pre-clinical development plan, which includes dose range finding studies, GLP toxicology studies, pharmacokinetic studies and other pre-clinical research, is anticipated to be completed during the 1st half of calendar year 2022, subject to the Company securing sufficient additional funding or entering into a strategic research and development partnership. After our satisfactory completion of all of the prerequisite pre-clinical in vitro and in vivo studies, an Investigational New Drug (IND) application would be filed with the FDA and, upon receiving FDA approval, we would initiate our Phase 1 clinical trial, subject to the Company securing sufficient additional funding or entering into the above-referenced strategic partnership.

In addition to our research and development activities related to our THC-glycoside compounds, we are expanding and diversifying our research and development activities to include the potential safety, efficacy and commercialization of our patented CBD-glycoside compounds. CBD has well-known anti-anxiety, anti-inflammatory and anti-microbial properties, but unlike THC, CBD is non-psychoactive and non-intoxicating. By glycosylating CBD, we can create CBD-glucose compounds that may enable a targeted and concentrated delivery of CBD in the gastrointestinal tract. Currently we are evaluating the optimal CBD-glycoside delivery mechanism, which may include an aqueous drink formulation since our glycosylation process significantly improves the water solubility of the CBD molecule.

Enzymatic Processing Methods

The Company originally developed its proprietary enzymatic bioprocessing technologies to attach glucose molecules to the molecules of stevia as part of our activities in the stevia processing industry. We then expanded the application of this proprietary technology to attach glucose molecules to cannabinoids, including THC and CBD. We may pursue additional opportunities to develop new products or license this technology.

Results of Operations

Three Months Ended December 31, 2020 and December 31, 2019

Our net income during the three months ended December 31, 2020, was $692,950 compared to a net loss of $795,295 for the three months ended December 31, 2019. This change was primarily attributable to a gain from a settlement of a vendor dispute. Included in net loss during the three months ended December 31, 2019, was our loss from discontinued operations of $48,769. There was no such loss recorded in the corresponding 2020 period. We had no revenue from continuing operations during either the 2020 or 2019 period.

During the three months ended December 31, 2020, we incurred general and administrative expenses in the aggregate amount of $394,567 compared to $506,926 incurred during the three months ended December 31, 2019 (a decrease of $112,359). General and administrative expenses generally include corporate overhead, salaries and other compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. The decrease in general and administrative costs in the period is primarily attributable to a decrease in employee benefits expense of approximately $37,000, as well as a decrease in travel expenses of approximately $21,000.

In addition, during the three months ended December 31, 2020, we incurred research and development costs of $71,975, compared to $241,840 during the three months ended December 31, 2019 (a decrease of $169,865). This decrease resulted from a reduction in staff in the 2020 period and corresponding decrease in research and development activities.

During the three months ended December 31, 2020, we recorded total net other income in the amount of $1,159,492, compared to total net other income recorded during the three months ended December 31, 2019 in the amount of $2,240. During the three months ended December 31, 2020, we recorded a gain from a settlement of a vendor dispute in the amount of $1,062,405 and a gain related to the forgiveness of our PPP loan of $97,516.

Nine Months Ended December 31, 2020 and December 31, 2019

Our net loss during the nine months ended December 31, 2020 was $520,220 compared to a net loss of $3,614,024 for the nine months ended December 31, 2019. The decrease in net loss of $3,093,804 during the 2020 period is attributable primarily to operating expenses reduced by $1,278,497, elimination of loss from discontinued operations of $714,827, gain on settlement of $1,062,405 and the gain related to the forgiveness of our PPP loan of $97,516. Included in net loss during the nine months ended December 31, 2019, was our loss from discontinued operations of $714,827. There was no loss from discontinued operations recorded in the 2020 period. We had no revenue from continuing operations during either the 2020 or 2019 period.

During the nine months ended December 31, 2020, we incurred general and administrative expenses in the aggregate amount of $1,342,110 compared to $2,094,026 incurred during the nine months ended December 31, 2019 (a decrease of $751,916). General and administrative expenses generally include corporate overhead, salaries and other compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. The majority of the decrease in general and administrative costs in the period is attributable to a decrease in legal fees, most of which were incurred in connection with the Private Investigation and Section 8(e) Examination, which decreased by approximately $500,000 from the previous nine-month period, as well as a decrease in wages of approximately $152,000 from the previous nine-month period.

In addition, during the nine months ended December 31, 2020, we incurred research and development costs of $338,268, compared to $864,849 during the nine months ended December 31, 2019 (a decrease of $526,581). This decrease resulted from a reduction in staff during the 2020 period and corresponding decrease in research and development activities.

Our discontinued operations incurred a loss of $714,827 during the nine months ended December 31, 2019. No loss from discontinued operations was incurred during the nine months ended December 31, 2020.

During the nine months ended December 31, 2020, we recorded total net other income in the amount of $1,160,158 compared to total net other income recorded during the nine months ended December 31, 2019 in the amount of $59,678. During the nine months ended December 31, 2020, we recorded a gain from a settlement of a vendor dispute in the amount of $1,062,405 and a gain related to the forgiveness of our PPP loan of $97,516.

Liquidity and Capital Resources

We have incurred losses since inception resulting in an accumulated deficit of $47,067,078 as of December 31, 2020, and further losses are anticipated in the development of our business.

As of December 31, 2020, we had total current assets of $1,454,666, comprised primarily of cash in the amount of $1,441,471. Our total current liabilities as of December 31, 2020 were $391,925, represented primarily by accounts payable and accrued liabilities of $72,078 and an advance of $296,653. As a result, on December 31, 2020, we had working capital of $1,062,741.

While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. We do not have any firm commitments for future capital and until the Company resumes ordinary course trading status on the OTCQB or a national exchange it will be difficult to obtain financing on commercially reasonable or acceptable terms. We do not presently have, nor do we expect in the near future to have, material revenue to fund our business from our operations, and we will need to obtain all of our necessary funding from external sources in the near term. Additional financing may be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Net Cash Used in Operating Activities

We have not generated positive cash flows from operating activities. For the nine months ended December 31, 2020, net cash used in operating activities-continuing operations was $1,047,742 compared to net cash used in operating activities-continuing operations of $2,144,458 for the nine months ended December 31, 2019. Net cash used in operating activities-continuing operations during the nine months ended December 31, 2020 consisted primarily of a net loss of $520,220, and a decrease in accounts payable of $178,045 offset by $349,546 related to stock-based compensation and gain on settlement of $612,405 net of the cash received. Net cash used in operating activities-continuing operations during the nine months ended December 31, 2019 consisted primarily of a net loss of $3,614,024, offset by $492,554 related to stock-based compensation and an increase in accounts payable of $292,521. For the nine months ended December 30, 2019, net cash used in operating activities-discontinued operations was $714,883. No cash was used in operating activities-discontinued operations for the nine months ended December 31, 2020. The losses incurred in the 2019 period were attributed to the losses incurred by the Company’s clinical operations.

Net Cash Used in Investing Activities

During the nine months ended December 31, 2020 and December 31, 2019, no net cash was used in or provided by investing activities.

Net Cash Provided By Financing Activities

During the nine months ended December 31, 2020, net cash provided from financing activities was $96,988 from the issuance of a note payable. During the nine months ended December 31, 2019, no net cash was used in or provided by financing activities.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to stockholders.

Critical Accounting Policies

Our financial statements and accompanying notes included in this report have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from the estimates made by management.

We believe the following critical accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements included in this report:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumption by management include, among others, the fair value of shares issued for services, the fair value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.

Share-Based Payments

The fair value of the Company’s stock options and warrants are estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Recent Accounting Pronouncements

Please refer to Footnote 1 of the accompanying financial statements for management’s discussion of recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We have established disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that information relating to the Company is accumulated and communicated to management, including our principal officers, as appropriate to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020, and have concluded that our disclosure controls and procedures were effective as of December 31, 2020.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to and our properties are not currently the subject of any material pending legal proceedings the adverse outcome of which, individually or in the aggregate, would be expected to have a material adverse effect on our financial position or results of operations.

Item 1A. Risk Factors

Please refer to the risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 29, 2020.

COVID-19 Considerations

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 6. Exhibits

Exhibit Number		Description of Exhibit

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.3		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

32.2		Certification of Chief Financial Officer Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema Document *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document *

† Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VITALITY BIOPHARMA, INC.

By:	/s/ Michael Cavanaugh
	Michael Cavanaugh
	Chief Executive Officer
	(Principal Executive Officer)


Date: January 29, 2021

EXHIBIT INDEX

Exhibit Number		Description of Exhibit

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.3		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

32.2		Certification of Chief Financial Officer Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema Document *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document *

† Furnished herewith.

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION

I, Michael Cavanaugh, certify that:

	1.	I have reviewed this report on Form 10-Q for the quarterly period ended December 31, 2020 of Vitality Biopharma, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 29, 2021

Name:	/s/ Michael Cavanaugh
By:	Michael Cavanaugh
Title:	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION

I, Richard McKilligan, certify that:

	1.	I have reviewed this report on Form 10-Q for the quarterly period ended December 31, 2020 of Vitality Biopharma, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 29, 2021

Name:	/s/ Richard McKilligan
By:	Richard McKilligan
Title:	Chief Financial Officer
	(Principal Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Michael Cavanaugh, the Chief Executive Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended December 31, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Michael Cavanaugh
Michael Cavanaugh
Chief Executive Officer
(Principal Executive Officer)

Date: January 29, 2021

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Richard McKilligan, the Chief Financial Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended December 31, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Richard McKilligan
Richard McKilligan
Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: January 29, 2021

EX-101.INS 6 vbio-20201231.xml XBRL INSTANCE FILE 0001438943 2019-03-31 0001438943 us-gaap:CommonStockMember 2019-03-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001438943 us-gaap:RetainedEarningsMember 2019-03-31 0001438943 2018-07-31 0001438943 2020-04-01 2020-12-31 0001438943 2020-03-31 0001438943 us-gaap:WarrantMember 2020-03-31 0001438943 us-gaap:CommonStockMember 2020-03-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001438943 us-gaap:RetainedEarningsMember 2020-03-31 0001438943 us-gaap:CommonStockMember 2019-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001438943 us-gaap:RetainedEarningsMember 2019-12-31 0001438943 2019-12-31 0001438943 VBIO:CommonStockOneMember 2016-08-19 0001438943 VBIO:CommonStockTwoMember 2016-08-19 0001438943 2019-09-30 0001438943 2020-12-31 0001438943 2019-04-01 2019-12-31 0001438943 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001438943 us-gaap:CommonStockMember 2019-04-01 2019-12-31 0001438943 us-gaap:CommonStockMember 2020-12-31 0001438943 us-gaap:CommonStockMember 2019-09-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001438943 us-gaap:RetainedEarningsMember 2020-04-01 2020-12-31 0001438943 us-gaap:RetainedEarningsMember 2019-04-01 2019-12-31 0001438943 us-gaap:RetainedEarningsMember 2020-12-31 0001438943 us-gaap:RetainedEarningsMember 2019-09-30 0001438943 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-12-31 0001438943 us-gaap:WarrantMember 2020-04-01 2020-12-31 0001438943 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-12-31 0001438943 us-gaap:WarrantMember 2019-04-01 2019-12-31 0001438943 VBIO:OperatingLeaseAgreementMember 2020-04-01 2020-12-31 0001438943 VBIO:OperatingLeaseAgreementMember 2019-04-01 2019-12-31 0001438943 VBIO:PaycheckProtectionProgramMember VBIO:USBankMember 2020-05-06 0001438943 VBIO:StockOptionsOneMember 2020-12-31 0001438943 VBIO:StockOptionsOneMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsTwoMember 2020-12-31 0001438943 VBIO:StockOptionsTwoMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsThreeMember 2020-12-31 0001438943 VBIO:StockOptionsThreeMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsFourMember 2020-12-31 0001438943 VBIO:StockOptionsFourMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsFiveMember 2020-12-31 0001438943 VBIO:StockOptionsFiveMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsSixMember 2020-12-31 0001438943 VBIO:StockOptionsSixMember srt:MaximumMember 2020-12-31 0001438943 VBIO:StockOptionsSixMember srt:MinimumMember 2020-12-31 0001438943 VBIO:StockOptionsSixMember srt:MaximumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsSixMember srt:MinimumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsSevenMember 2020-12-31 0001438943 VBIO:StockOptionsSevenMember srt:MinimumMember 2020-12-31 0001438943 VBIO:StockOptionsSevenMember srt:MaximumMember 2020-12-31 0001438943 VBIO:StockOptionsSevenMember srt:MinimumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsSevenMember srt:MaximumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsEightMember 2020-12-31 0001438943 VBIO:StockOptionsEightMember srt:MinimumMember 2020-12-31 0001438943 VBIO:StockOptionsEightMember srt:MinimumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsEightMember srt:MaximumMember 2020-12-31 0001438943 VBIO:StockOptionsEightMember srt:MaximumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsNineMember 2020-12-31 0001438943 VBIO:StockOptionsNineMember srt:MinimumMember 2020-12-31 0001438943 VBIO:StockOptionsNineMember srt:MinimumMember 2020-04-01 2020-12-31 0001438943 VBIO:StockOptionsNineMember srt:MaximumMember 2020-12-31 0001438943 VBIO:StockOptionsNineMember srt:MaximumMember 2020-04-01 2020-12-31 0001438943 us-gaap:WarrantMember 2020-12-31 0001438943 us-gaap:WarrantMember 2020-04-01 2020-12-31 0001438943 2020-10-01 2020-12-31 0001438943 2019-10-01 2019-12-31 0001438943 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001438943 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001438943 us-gaap:CommonStockMember 2020-09-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001438943 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001438943 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001438943 us-gaap:RetainedEarningsMember 2020-09-30 0001438943 2020-09-30 0001438943 2021-01-28 0001438943 VBIO:PaycheckProtectionProgramMember 2020-11-20 2020-11-21 0001438943 VBIO:PaycheckProtectionProgramMember 2020-11-21 0001438943 2020-11-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD

0.001

1000000000

50840147

100789

93845

45970

139218

Vitality Biopharma, Inc. 10-Q 2020-12-31 false --03-31 Yes Yes Non-accelerated Filer true false false Q3 2021

15666

13195

2407891

1454666

35752

26157

2567249

1503640

862528

72078

125679

23194

1284860

391925

50640

47778607

48128153

-46546858

-47067078

2567249

1503640

1342110

2094026

394567

506926

338268

864849

71975

241840

1680378

2958875

466542

748766

-1680378

-2958875

-466542

-748766

123606

22817

2392225

1441471

250000 296653 296653

1284860

391925

0001438943

1160158

59678

1159492

2240

35625

1711

-520220

-2899197

692950

-746526

-714827

-48769

-520220

-3614024

-520220

-3614024

692950

-795295

692950

-0.01

-0.00

-0.01

-0.06

0.01

-0.01

50840147

51773420

50840147

5021076

52090

47150489

-42181503

1282389

50640

47778607

-46546858

50640

47644493

-45795527

1899606

2552619

1111715

50640

48128153

47502211

-47067078

-45000232

50640

48015844

-47760028

306456

52290147

50840147

349546

492554

349546

492554

112309

142282

112309

-1450

1450

-1450000

-714883

-1047742

-2144458

-102485

-97954

-5200

-178045

292521

-2471

-24598

349546

492554

-1047742

-2859341

96988

-950754

-2859341

5982741

2392225

3123400

1441471

248425

50840147

97516

1062405 1062405 528 1450 450000

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.   The Company is engaged in the research and development of cannabinoid prodrug pharmaceuticals, which we refer to as cannabosides. We discovered these cannabosides through application of the Company’s proprietary enzymatic bioprocessing technologies. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.   Liquidity   Since we do not have any commercial products currently available in the marketplace, the Company does not generate any revenues. As reflected in the accompanying financial statements, during the nine months ended December 31, 2020, the Company incurred a net loss of $520,220 and used $1,047,742 of cash in our operating activities. As of December 31, 2020, we had $1,441,471 of cash on hand, stockholders’ equity of $1,111,715 and had working capital of $1,062,741.   Our total expenditures for the twelve months following December 31, 2020, are expected to be approximately $1,000,000, which is comprised of research and development and general operating expenses. Based on the funds we had available on December 31, 2020, we believe that we have sufficient capital to fund our anticipated operating expenses for at least one year from the date that the financial statements in this report are issued.   On November 7, 2018, the SEC suspended the trading of our common stock. Our common stock resumed trading with limited liquidity on the grey market on November 21, 2018. Grey market stocks are not traded or quoted on an exchange or inter-dealer quotation system, but are reported by broker-dealers to their self-regulatory organization (“SRO”) and the SRO distributes the trade data to market data vendors and financial websites. Since grey market securities are not traded or quoted on an exchange or inter-dealer quotation system, investor’s bids and offers are not collected in a central spot, so market transparency is diminished and execution of orders is difficult. We are actively pursuing the resumption of ordinary course trading status on the OTCQB.   In September 2020, we retained DelMorgan & Co., an internationally recognized investment banking firm, to advise us on our strategic alternatives, including potential financings, asset divestitures or strategic partnerships. The Company is continuing to work closely with DelMorgan in support of their retention.   While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. We do not have any firm commitments for future capital and until the Company’s securities resume ordinary course trading on the OTCQB (or are listed on a national exchange) it will be difficult to obtain financing on commercially reasonable or acceptable terms. We do not presently have, nor do we expect in the near future to have, material revenue to fund our business from our operations, and we will need to obtain all of our necessary funding from external sources in the near term. Additional financing may be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership may be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.   Further, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect.   COVID-19 Considerations   The global outbreak of COVID-19 has led to significant disruptions in the global economy, including the curtailment of activities by businesses and consumers in much of the world as governments and others seek to limit the spread of the disease. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures imposed by domestic and foreign governments, the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. In the quarter ended December 31, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. We have also not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.   Basis of Presentation of Unaudited Condensed Financial Information   The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2020 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2020. These financial statements should be read in conjunction with that report.   Estimates   The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.   Financial Assets and Liabilities Measured at Fair Value   The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify">Level 1</td> <td style="text-align: justify"> </td> <td style="text-align: justify">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify">Level 2</td> <td style="width: 14px; text-align: justify"> </td> <td style="text-align: justify">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Level 3</td> <td style="text-align: justify"> </td> <td style="text-align: justify">Unobservable inputs based on the Company’s assumptions.</td></tr> </table>   The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts payable, notes payable and advance, approximate their fair values because of the short maturity of these instruments.   Derivative Financial Instruments   The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.   Share-Based Payments   The Company periodically issues stock options, warrants, and shares of common stock as share-based compensation to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on FASB ASC 718, Compensation – Stock Compensation (Topic 718) whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.   The fair value of the Company’s stock options and warrants are estimated using the Black-Scholes-Merton Option Pricing model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.   Basic and Diluted Loss Per Share   Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine months ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">5,997,544</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">6,546,710</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">146,668</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,135,003</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,144,212</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7,681,713</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates. Research and development costs are expensed as incurred.   Recent Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning April 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.   In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. OPERATING LEASE   At December 31, 2020, the Company’s wholly-owned subsidiary, The Control Center, Inc., (“TCC”) has an operating lease agreement for office space that began in December 2012, and was amended in December 2015 and December 2019, and expires February 28, 2021. In addition, at December 31, 2020, TCC has a sublease agreement in place for the office space that began in September 2019 and expires February 28, 2021. TCC remains the primary obligor on the office space lease agreement. Sublease income was not significant during the three and nine months ended December 31, 2020 and 2019.   Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its lease as a single lease component. Lease expense is recognized on a straight-line basis over the lease term. An operating lease right-of-use (“ROU”) asset and liability is recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments.   The components of lease expense and supplemental cash flow information related to leases for the period are as follows:  <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Lease Cost</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed consolidated statement of operations)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">111,657</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Information</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted average remaining lease term – operating leases (in years)</td> <td> </td> <td> </td> <td style="text-align: right">0.2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Average discount rate – operating leases</td> <td> </td> <td> </td> <td style="text-align: right">4.0</td> <td>%</td></tr> </table>   The supplemental balance sheet information related to leases for the period is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">At December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating leases</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; padding-bottom: 1.5pt">Long-term right-of-use asset</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: right">22,817</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Short-term operating lease liability</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,194</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total operating lease liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">23,194</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Maturities of the Company’s lease liabilities are as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Year Ending March 31</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Operating Lease</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-bottom: 1.5pt">2021 (remaining 2 months)</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: right">23,310</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total lease payments</td> <td> </td> <td> </td> <td style="text-align: right">23,310</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Less: Imputed interest/present value discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(116</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Present value of lease liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">23,194</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Lease expenses were $45,970 and $139,218 during the three and nine months ended December 31, 2020, respectively.

4. GAIN ON SETTLEMENT   From 2016 to 2019, the Company recorded approximately $1.1 million due to a vendor for services, of which $612,405 had not been paid and was included in accounts payable at March 31, 2020 and through November 30, 2020.  In December 2020, the Company reached a settlement with the vendor to forgive the $612,405 of outstanding invoices, and in addition, the Company received a payment from the vendor of $450,000.  This resulted in a gain on settlement of $1,062,405 during the three and nine months ended December 31, 2020. 5. ADVANCE   In July 2018, we received a payment from a third party in the amount of $250,000 and a payment of $46,653 was made on our behalf to a vendor. To date, the Company has not confirmed the nature of these payments. We have recorded these payments as an advance and at December 31, 2020 and March 31, 2020, it is included in current liabilities on the accompanying financial statements.

6. STOCK OPTIONS   A summary of the Company’s stock option activity during the nine months ended December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance outstanding at March 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">6,556,710</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">0.89</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">(32,500</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">2.17</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(526,666</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.42</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance outstanding at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,997,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.91</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance exercisable at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,622,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.87</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   A summary of the Company’s stock options outstanding and exercisable as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Grant- date Stock Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Options Outstanding, December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">750,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,664,542</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">128,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">130,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,834</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">657,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">123,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,997,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Options Exercisable, December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.30</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,664,542</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">128,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">130,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,834</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ $ 1.50 - 1.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">657,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">123,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,622,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the nine months ended December 31, 2020, we expensed total stock-based compensation related to stock options of $349,546, and the remaining unamortized cost of the outstanding stock-based awards at December 31, 2020 was approximately $160,000. The remaining unamortized cost will be amortized on a straight-line basis over a weighted average remaining vesting period of one year. At December 31, 2020, the 5,997,044 outstanding stock options had no intrinsic value.

7. WARRANTS   A summary of warrants to purchase the Company’s common stock during the nine months ended December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance outstanding at March 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,135,003</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">2.19</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(988,335</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.10</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance outstanding and exercisable at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">146,668</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3.00</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   At December 31, 2020, the 146,668 outstanding stock warrants had no intrinsic value.

8. DISCONTINUED OPERATIONS   In October 2018, the Company acquired Summit Healthtech, Inc. (renamed Vitality Healthtech, Inc.), a specialty healthcare clinic. In addition to Summit Healthcare, the Company sold research diagnostic testing kits (collectively, the Company’s clinical and test kit operations). In May 2019 the Company decided to close its clinical and test kit operations. The clinical and test kit operations meet the discontinued operations criteria and are reported as such in all periods presented on the accompanying condensed consolidated financial statements.   The following table presents the summarized components of loss from discontinued operations for the clinical and test kit operations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">48,769</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(48,769</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">44,698</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">143,232</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,361</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">611,932</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(714,827</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

9. COMMITMENTS AND CONTINGENCIES   SEC Investigation   On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. On May 12, 2020, our outside legal counsel received a letter from the staff of the SEC’s Enforcement Division stating that it has concluded the investigation as to the Company, and that it did not intend to recommend an enforcement action by the SEC against the Company. While certain former officers and directors may request the Company to reimburse them for legal fees related to this matter, at December 31, 2020, management has determined that the Company’s liability for those fees is not probable and we could not reasonably estimate those fees.

Liquidity   Since we do not have any commercial products currently available in the marketplace, the Company does not generate any revenues. As reflected in the accompanying financial statements, during the nine months ended December 31, 2020, the Company incurred a net loss of $520,220 and used $1,047,742 of cash in our operating activities. As of December 31, 2020, we had $1,441,471 of cash on hand, stockholders’ equity of $1,111,715 and had working capital of $1,062,741.   Our total expenditures for the twelve months following December 31, 2020, are expected to be approximately $1,000,000, which is comprised of research and development and general operating expenses. Based on the funds we had available on December 31, 2020, we believe that we have sufficient capital to fund our anticipated operating expenses for at least one year from the date that the financial statements in this report are issued.   On November 7, 2018, the SEC suspended the trading of our common stock. Our common stock resumed trading with limited liquidity on the grey market on November 21, 2018. Grey market stocks are not traded or quoted on an exchange or inter-dealer quotation system, but are reported by broker-dealers to their self-regulatory organization (“SRO”) and the SRO distributes the trade data to market data vendors and financial websites. Since grey market securities are not traded or quoted on an exchange or inter-dealer quotation system, investor’s bids and offers are not collected in a central spot, so market transparency is diminished and execution of orders is difficult. We are actively pursuing the resumption of ordinary course trading status on the OTCQB.   In September 2020, we retained DelMorgan & Co., an internationally recognized investment banking firm, to advise us on our strategic alternatives, including potential financings, asset divestitures or strategic partnerships. The Company is continuing to work closely with DelMorgan in support of their retention.   While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. We do not have any firm commitments for future capital and until the Company’s securities resume ordinary course trading on the OTCQB (or are listed on a national exchange) it will be difficult to obtain financing on commercially reasonable or acceptable terms. We do not presently have, nor do we expect in the near future to have, material revenue to fund our business from our operations, and we will need to obtain all of our necessary funding from external sources in the near term. Additional financing may be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership may be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.   Further, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. COVID-19 Considerations   The global outbreak of COVID-19 has led to significant disruptions in the global economy, including the curtailment of activities by businesses and consumers in much of the world as governments and others seek to limit the spread of the disease. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures imposed by domestic and foreign governments, the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. In the quarter ended December 31, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. We have also not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.

Basis of Presentation of Unaudited Condensed Financial Information   The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2020 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2020. These financial statements should be read in conjunction with that report.

Estimates   The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

Financial Assets and Liabilities Measured at Fair Value   The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify">Level 1</td> <td style="text-align: justify"> </td> <td style="text-align: justify">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify">Level 2</td> <td style="width: 14px; text-align: justify"> </td> <td style="text-align: justify">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Level 3</td> <td style="text-align: justify"> </td> <td style="text-align: justify">Unobservable inputs based on the Company’s assumptions.</td></tr> </table>   The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts payable, notes payable and advance, approximate their fair values because of the short maturity of these instruments.

Derivative Financial Instruments   The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Share-Based Payments   The Company periodically issues stock options, warrants, and shares of common stock as share-based compensation to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on FASB ASC 718, Compensation – Stock Compensation (Topic 718) whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.   The fair value of the Company’s stock options and warrants are estimated using the Black-Scholes-Merton Option Pricing model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Basic and Diluted Loss Per Share   Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine months ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">5,997,544</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">6,546,710</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">146,668</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,135,003</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,144,212</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7,681,713</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates. Research and development costs are expensed as incurred.

Recent Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning April 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.   In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine months ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">5,997,544</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">6,546,710</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">146,668</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,135,003</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,144,212</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7,681,713</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:  <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Lease Cost</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed consolidated statement of operations)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">111,657</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Information</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted average remaining lease term – operating leases (in years)</td> <td> </td> <td> </td> <td style="text-align: right">0.2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Average discount rate – operating leases</td> <td> </td> <td> </td> <td style="text-align: right">4.0</td> <td>%</td></tr> </table>

Maturities of the Company’s lease liabilities are as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Year Ending March 31</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Operating Lease</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-bottom: 1.5pt">2021 (remaining 2 months)</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: right">23,310</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total lease payments</td> <td> </td> <td> </td> <td style="text-align: right">23,310</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Less: Imputed interest/present value discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(116</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Present value of lease liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">23,194</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the Company’s stock option activity during the nine months ended December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance outstanding at March 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">6,556,710</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">0.89</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">(32,500</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">2.17</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(526,666</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.42</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance outstanding at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,997,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.91</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance exercisable at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,622,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.87</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the Company’s stock options outstanding and exercisable as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Grant- date Stock Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Options Outstanding, December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">750,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,664,542</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">128,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">130,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,834</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">657,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">123,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,997,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Options Exercisable, December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.30</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,664,542</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">128,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.96</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">130,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,834</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 1.50 - 1.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ $ 1.50 - 1.95</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">657,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 2.00 - 2.79</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">123,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$ 3.10 - 3.80</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">$ 4.00 - 4.70</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,622,544</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of warrants to purchase the Company’s common stock during the nine months ended December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance outstanding at March 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,135,003</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">2.19</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(988,335</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.10</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance outstanding and exercisable at December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">146,668</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3.00</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table presents the summarized components of loss from discontinued operations for the clinical and test kit operations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">48,769</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(48,769</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">44,698</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">143,232</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,361</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">611,932</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(714,827</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

612405

1441471

1062741 1000000

6144212

7681713

5997544

146668

6546710

1135003

P12M

111657

P0Y2M12D

0.040

23194

23310

116

96988

0.01

97516

528

160000

P1Y

6556710

5997544

750000

2000000

1664542

128000

130000

500834

657500

123334

43334

32500

526666

4622544

375000

1000000

1664542

128000

130000

500834

657500

123334

43334

0.89

0.91

0.30

0.35

0.50

0.96

10.00

1.95

1.50

2.00

2.79

3.10

3.80

4.00

4.70

2.17

1.42

0.87

0.30

0.35

0.50

0.96

1.00

1.95

1.50

2.00

2.79

3.10

3.80

4.00

4.70

0.30

0.35

0.50

0.96

1.00

1.95

1.50

2.00

2.79

3.10

3.80

4.00

4.70

0.30 0.35 0.50 0.96 10.00 1.95 1.50 2.00 2.79 3.10 3.80 4.00 4.70

146668

1135003

146668

988335

2.19 2.10 3.00

44698

143232

4361

611932

48769

-714827

-48769

2650000

7950000

237 24053 -429 529 9595 -10000

3. GAIN ON EXTINGUISHMENT OF NOTE PAYABLE   On May 6, 2020, the Company was granted a loan (the “PPP” loan) from U.S. Bank for $96,988 pursuant to the Paycheck Protection Program under the CARES Act. The PPP loan bore interest at 1% per annum with the first six months of interest deferred, and was unsecured and guaranteed by the Small Business Administration (the “SBA”). The Company used the entire PPP loan amount for qualifying expenses as described in the CARES Act, including qualifying payroll costs, qualifying group health care benefits, qualifying rent, and qualifying utilities. On November 21, 2020, we received notice that the SBA had reviewed the forgiveness application of our PPP loan and provided forgiveness of our PPP loan of $97,516, including accrued interest of $528. We recognized a gain on extinguishment of the PPP loan of $97,516 during the three and nine months ended December 31, 2020.

The supplemental balance sheet information related to leases for the period is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">At December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating leases</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%; padding-bottom: 1.5pt">Long-term right-of-use asset</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: right">22,817</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Short-term operating lease liability</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,194</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total operating lease liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">23,194</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> -520220 -2899197 1100000 612405 450000

46653

EX-101.SCH 7 vbio-20201231.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes In Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Operating Lease link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Gain on Extinguishment of Note Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Gain on Settlement link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Advance link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Operating Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Operating Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Operating Lease - Schedule of Lease Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Operating Lease - Schedule of Supplement Related to Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Operating Lease - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Gain on Extinguishment of Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Gain on Settlement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Advance (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Warrants - Summary of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vbio-20201231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 vbio-20201231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 vbio-20201231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in-Capital [Member] Accumulated Deficit [Member] Warrants [Member] Common Stock One [Member] Common Stock Two [Member] Antidilutive Securities [Axis] Options [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Operating Lease Agreement [Member] Paycheck Protection Program [Member] Legal Entity [Axis] U.S. Bank [Member] Award Type [Axis] Stock Options One [Member] Stock Options Two [Member] Stock Options Three [Member] Stock Options Four [Member] Stock Options Five [Member] Stock Options Six [Member] Range [Axis] Maximum [Member] Minimum [Member] Stock Options Seven [Member] Stock Options Eight [Member] Stock Options Nine[Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash and cash equivalents Prepaid expenses and other current assets Total current assets Deposits Operating lease right-of-use asset Total Assets Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued liabilities Advance Operating lease liability, short-term Total current liabilities Total liabilities Commitments and contingencies Stockholders' Equity Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 50,840,147 shares issued and outstanding Additional paid-in-capital Accumulated deficit Total stockholders' equity Total Liabilities and Stockholders' Equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating expenses: General and administrative Research and development Total operating expenses Loss from operations Other income (expense) Change in fair value of derivative liability Gain on extinguishment of note payable Gain on settlement Other Total other income (expense), net Income (loss) from continuing operations Loss from discontinued operations Net income (loss) Net income (loss) per common share - Income (loss) from continuing operations Loss from discontinued operations Weighted average number of common shares outstanding Basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Cancellation of shares Cancellation of shares, shares Fair value of vested stock options Net income loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Loss from discontinued operations Loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities Fair value of vested stock options Operating lease expense Change in fair value of derivative liability Gain on settlement, net of cash received of $450,000 Gain on extinguishment of note payable Accrual of interest added to note payable Changes in operating assets and liabilities: Prepaid expense and other current assets Deposits Accounts payable and accrued liabilities Accounts payable - related party Operating lease liability Net cash used in operating activities- continuing operations Net cash used in operating activities- discontinued operations Net cash used in operating activities Cash flows from financing activities: Proceeds from note payable Net cash provided by financing activities Net decrease in cash Cash and cash equivalents - beginning of period Cash and cash equivalent - end of period Supplemental disclosure of cash flow information: Cash paid during the period for: Interest Cash paid during the period for: Income taxes Supplemental non-cash investing and financing activities: Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of new lease accounting standard Cancellation of shares Cash received on settlement Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Operations and Summary of Significant Accounting Policies Leases [Abstract] Operating Lease Debt Disclosure [Abstract] Gain On Extinguishment of Note Payable Gain On Settlement Receivables [Abstract] Advance Share-based Payment Arrangement [Abstract] Stock Options Warrants and Rights Note Disclosure [Abstract] Warrants Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Liquidity Covid-19 Considerations Basis of Presentation of Unaudited Condensed Financial Information Estimates Financial Assets and Liabilities Measured at Fair Value Derivative Financial Instruments Share-based Payments Basic and Diluted Loss Per Share Research and Development Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Lease Expenses Schedule of Supplement Related to Lease Schedule of Maturities of Lease Liabilities Summary of Stock Option Activity Schedule of Stock Options Outstanding and Exercisable Summary of Warrants Activity Schedule of Discontinued Operations for Summit Healthcare Net cash used in operating activities Cash on hand Stockholders' equity Working capital Total expected expenditure for operating expenses and investment activity Antidilutive securities excluded from computation of earnings per share Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Operating lease remaining lease term Lease expenses Operating lease cost (included in general and administrative expenses in the Company's unaudited condensed consolidated statement of operations) Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020 Weighted average remaining lease term - operating leases (in years) Average discount rate - operating leases Operating Leases: Long-term right-of-use asset Operating Leases: Short-term operating lease liability Operating Leases: Total operating lease liabilities 2021 (remaining 2 months) Total lease payments Less: Imputed interest/present value discount Present value of lease liabilities Loans payable Debt instrument, interest rate Forgiveness of loan Accrued interest Gain on extinguishment of loan Gain On Settlement Due to vendor Accounts payable to vendor Gain on settlement of outstanding invoices Payment from vendor Other current liabilities Stock-based compensation expense EX-101.PRE 11 vbio-20201231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Dec. 31, 2020	Jan. 28, 2021
Cover [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	0001438943
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,840,147
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 1,441,471	$ 2,392,225
Prepaid expenses and other current assets	13,195	15,666
Total current assets	1,454,666	2,407,891
Deposits	26,157	35,752
Operating lease right-of-use asset	22,817	123,606
Total Assets	1,503,640	2,567,249
Current Liabilities
Accounts payable and accrued liabilities	72,078	862,528
Advance	296,653	296,653
Operating lease liability, short-term	23,194	125,679
Total current liabilities	391,925	1,284,860
Total liabilities	391,925	1,284,860
Commitments and contingencies
Stockholders' Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 50,840,147 shares issued and outstanding	50,640	50,640
Additional paid-in-capital	48,128,153	47,778,607
Accumulated deficit	(47,067,078)	(46,546,858)
Total stockholders' equity	1,111,715	1,282,389
Total Liabilities and Stockholders' Equity	$ 1,503,640	$ 2,567,249

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	50,840,147	50,840,147
Common stock, shares outstanding	50,840,147	50,840,147

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues
Operating expenses:
General and administrative	394,567	506,926	1,342,110	2,094,026
Research and development	71,975	241,840	338,268	864,849
Total operating expenses	466,542	748,766	1,680,378	2,958,875
Loss from operations	(466,542)	(748,766)	(1,680,378)	(2,958,875)
Other income (expense)
Change in fair value of derivative liability		1,711		35,625
Gain on extinguishment of note payable	97,516		97,516
Gain on settlement	1,062,405		1,062,405
Other	(429)	529	237	24,053
Total other income (expense), net	1,159,492	2,240	1,160,158	59,678
Income (loss) from continuing operations	692,950	(746,526)	(520,220)	(2,899,197)
Loss from discontinued operations		(48,769)		(714,827)
Net income (loss)	$ 692,950	$ (795,295)	$ (520,220)	$ (3,614,024)
Net income (loss) per common share - Income (loss) from continuing operations	$ 0.01	$ (0.01)	$ (0.01)	$ (0.06)
Loss from discontinued operations		$ (0.00)		$ (0.01)
Weighted average number of common shares outstanding Basic and diluted	50,840,147	50,840,147	50,840,147	51,773,420

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes In Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 31, 2019	$ 52,090	$ 47,150,489	$ (42,181,503)	$ 5,021,076
Balance, shares at Mar. 31, 2019	52,290,147
Cancellation of shares	$ (1,450)	1,450
Cancellation of shares, shares	(1,450,000)
Fair value of vested stock options		492,554		492,554
Net income loss			(3,614,024)	(3,614,024)
Balance at Dec. 31, 2019	$ 50,640	47,644,493	(45,795,527)	1,899,606
Balance, shares at Dec. 31, 2019	50,840,147
Balance at Sep. 30, 2019	$ 50,640	47,502,211	(45,000,232)	2,552,619
Balance, shares at Sep. 30, 2019	50,840,147
Fair value of vested stock options		142,282		142,282
Net income loss			(795,295)	(795,295)
Balance at Dec. 31, 2019	$ 50,640	47,644,493	(45,795,527)	1,899,606
Balance, shares at Dec. 31, 2019	50,840,147
Balance at Mar. 31, 2020	$ 50,640	47,778,607	(46,546,858)	1,282,389
Balance, shares at Mar. 31, 2020	50,840,147
Fair value of vested stock options		349,546		349,546
Net income loss			(520,220)	(520,220)
Balance at Dec. 31, 2020	$ 50,640	48,128,153	(47,067,078)	1,111,715
Balance, shares at Dec. 31, 2020	50,840,147
Balance at Sep. 30, 2020	$ 50,640	$ 48,015,844	$ (47,760,028)	$ 306,456
Balance, shares at Sep. 30, 2020	50,840,147
Fair value of vested stock options		$ 112,309		$ 112,309
Net income loss			692,950	692,950
Balance at Dec. 31, 2020	$ 50,640	$ 48,128,153	$ (47,067,078)	$ 1,111,715
Balance, shares at Dec. 31, 2020	50,840,147

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (520,220)	$ (3,614,024)
Loss from discontinued operations		714,827
Loss from continuing operations	(520,220)	(2,899,197)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of vested stock options	349,546	492,554
Operating lease expense	100,789	93,845
Change in fair value of derivative liability		(35,625)
Gain on settlement, net of cash received of $450,000	(612,405)
Gain on extinguishment of note payable	(97,516)
Accrual of interest added to note payable	528
Changes in operating assets and liabilities:
Prepaid expense and other current assets	2,471	24,598
Deposits	9,595	(10,000)
Accounts payable and accrued liabilities	(178,045)	292,521
Accounts payable - related party		(5,200)
Operating lease liability	(102,485)	(97,954)
Net cash used in operating activities- continuing operations	(1,047,742)	(2,144,458)
Net cash used in operating activities- discontinued operations		(714,883)
Net cash used in operating activities	(1,047,742)	(2,859,341)
Cash flows from financing activities:
Proceeds from note payable	96,988
Net cash provided by financing activities	96,988
Net decrease in cash	(950,754)	(2,859,341)
Cash and cash equivalents - beginning of period	2,392,225	5,982,741
Cash and cash equivalent - end of period	1,441,471	3,123,400
Supplemental disclosure of cash flow information:
Cash paid during the period for: Interest
Cash paid during the period for: Income taxes
Supplemental non-cash investing and financing activities:
Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of new lease accounting standard		248,425
Cancellation of shares		$ 1,450

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	9 Months Ended
	Dec. 31, 2020 USD ($)
Statement of Cash Flows [Abstract]
Cash received on settlement	$ 450,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies

9 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Operations and Summary of Significant Accounting Policies

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

Liquidity

COVID-19 Considerations

Basis of Presentation of Unaudited Condensed Financial Information

Estimates

Financial Assets and Liabilities Measured at Fair Value

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

Derivative Financial Instruments

Share-Based Payments

Basic and Diluted Loss Per Share

	Nine months ended
	December 31, 2020		December 31, 2019
Options		5,997,544		6,546,710
Warrants		146,668		1,135,003
Total		6,144,212		7,681,713

Research and Development

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Operating Lease

9 Months Ended

Dec. 31, 2020

Leases [Abstract]

Operating Lease

2. OPERATING LEASE

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Nine Months Ended December 31, 2020
Lease Cost
Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed consolidated statement of operations)	$	111,657

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020	$	-
Weighted average remaining lease term – operating leases (in years)		0.2
Average discount rate – operating leases		4.0	%

The supplemental balance sheet information related to leases for the period is as follows:

	At December 31, 2020
Operating leases
Long-term right-of-use asset	$	22,817

Short-term operating lease liability	$	23,194
Total operating lease liabilities	$	23,194

Maturities of the Company’s lease liabilities are as follows (in thousands):

Year Ending March 31	Operating Lease
2021 (remaining 2 months)	$	23,310
Total lease payments		23,310
Less: Imputed interest/present value discount		(116	)
Present value of lease liabilities	$	23,194

Lease expenses were $45,970 and $139,218 during the three and nine months ended December 31, 2020, respectively.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Gain on Extinguishment of Note Payable

9 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Gain On Extinguishment of Note Payable

3. GAIN ON EXTINGUISHMENT OF NOTE PAYABLE

XML 22 R11.htm IDEA: XBRL DOCUMENT

Gain on Settlement

9 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Gain On Settlement

4. GAIN ON SETTLEMENT

XML 23 R12.htm IDEA: XBRL DOCUMENT

Advance

9 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Advance

5. ADVANCE

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock Options

9 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock Options

6. STOCK OPTIONS

A summary of the Company’s stock option activity during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		6,556,710		$	0.89
Granted		-
Exercised		-
Expired		(32,500	)		2.17
Cancelled		(526,666	)		1.42
Balance outstanding at December 31, 2020		5,997,544		$	0.91
Balance exercisable at December 31, 2020		4,622,544		$	0.87

A summary of the Company’s stock options outstanding and exercisable as of December 31, 2020 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, December 31, 2020		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		5,997,544
Options Exercisable, December 31, 2020		375,000	$	0.30	$	0.30
		1,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ $ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		4,622,544

XML 25 R14.htm IDEA: XBRL DOCUMENT

Warrants

9 Months Ended

Dec. 31, 2020

Warrants and Rights Note Disclosure [Abstract]

Warrants

7. WARRANTS

A summary of warrants to purchase the Company’s common stock during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		1,135,003		$	2.19
Granted		-			-
Exercised		-			-
Expired		(988,335	)		2.10
Balance outstanding and exercisable at December 31, 2020		146,668		$	3.00

At December 31, 2020, the 146,668 outstanding stock warrants had no intrinsic value.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Dec. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

8. DISCONTINUED OPERATIONS

The following table presents the summarized components of loss from discontinued operations for the clinical and test kit operations:

	Three Months Ended December 31,
	2020		2019

Revenue	$	-	$	-

Cost of sales		-		-
Research and development		-		-
General and administrative		-		48,769
Loss from discontinued operations	$	-	$	(48,769	)

	Nine Months Ended December 31,
	2020		2019

Revenue	$	-	$	44,698

Cost of sales		-		143,232
Research and development		-		4,361
General and administrative		-		611,932
Loss from discontinued operations	$	-	$	(714,827	)

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

SEC Investigation

XML 28 R17.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity

Covid-19 Considerations

COVID-19 Considerations

Basis of Presentation of Unaudited Condensed Financial Information

Estimates

Financial Assets and Liabilities Measured at Fair Value

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

Derivative Financial Instruments

Share-based Payments

Share-Based Payments

Basic and Diluted Loss Per Share

	Nine months ended
	December 31, 2020		December 31, 2019
Options		5,997,544		6,546,710
Warrants		146,668		1,135,003
Total		6,144,212		7,681,713

Research and Development

Recent Accounting Pronouncements

XML 29 R18.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

	Nine months ended
	December 31, 2020		December 31, 2019
Options		5,997,544		6,546,710
Warrants		146,668		1,135,003
Total		6,144,212		7,681,713

XML 30 R19.htm IDEA: XBRL DOCUMENT

Operating Lease (Tables)

9 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Lease Expenses

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Nine Months Ended December 31, 2020
Lease Cost
Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed consolidated statement of operations)	$	111,657

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020	$	-
Weighted average remaining lease term – operating leases (in years)		0.2
Average discount rate – operating leases		4.0	%

Schedule of Supplement Related to Lease

The supplemental balance sheet information related to leases for the period is as follows:

	At December 31, 2020
Operating leases
Long-term right-of-use asset	$	22,817

Short-term operating lease liability	$	23,194
Total operating lease liabilities	$	23,194

Schedule of Maturities of Lease Liabilities

Maturities of the Company’s lease liabilities are as follows (in thousands):

Year Ending March 31	Operating Lease
2021 (remaining 2 months)	$	23,310
Total lease payments		23,310
Less: Imputed interest/present value discount		(116	)
Present value of lease liabilities	$	23,194

XML 31 R20.htm IDEA: XBRL DOCUMENT

Stock Options (Tables)

9 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		6,556,710		$	0.89
Granted		-
Exercised		-
Expired		(32,500	)		2.17
Cancelled		(526,666	)		1.42
Balance outstanding at December 31, 2020		5,997,544		$	0.91
Balance exercisable at December 31, 2020		4,622,544		$	0.87

Schedule of Stock Options Outstanding and Exercisable

A summary of the Company’s stock options outstanding and exercisable as of December 31, 2020 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, December 31, 2020		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		5,997,544
Options Exercisable, December 31, 2020		375,000	$	0.30	$	0.30
		1,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		500,834		$ 1.50 - 1.95		$ $ 1.50 - 1.95
		657,500		$ 2.00 - 2.79		$ 2.00 - 2.79
		123,334		$ 3.10 - 3.80		$ 3.10 - 3.80
		43,334		$ 4.00 - 4.70		$ 4.00 - 4.70
		4,622,544

XML 32 R21.htm IDEA: XBRL DOCUMENT

Warrants (Tables)

9 Months Ended

Dec. 31, 2020

Warrants and Rights Note Disclosure [Abstract]

Summary of Warrants Activity

A summary of warrants to purchase the Company’s common stock during the nine months ended December 31, 2020 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2020		1,135,003		$	2.19
Granted		-			-
Exercised		-			-
Expired		(988,335	)		2.10
Balance outstanding and exercisable at December 31, 2020		146,668		$	3.00

XML 33 R22.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

9 Months Ended

Dec. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations for Summit Healthcare

The following table presents the summarized components of loss from discontinued operations for the clinical and test kit operations:

	Three Months Ended December 31,
	2020		2019

Revenue	$	-	$	-

Cost of sales		-		-
Research and development		-		-
General and administrative		-		48,769
Loss from discontinued operations	$	-	$	(48,769	)

	Nine Months Ended December 31,
	2020		2019

Revenue	$	-	$	44,698

Cost of sales		-		143,232
Research and development		-		4,361
General and administrative		-		611,932
Loss from discontinued operations	$	-	$	(714,827	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 692,950	$ (795,295)	$ (520,220)	$ (3,614,024)
Net cash used in operating activities			(1,047,742)	(2,859,341)
Cash on hand	1,441,471		1,441,471
Stockholders' equity	1,111,715	$ 1,899,606	1,111,715	$ 1,899,606	$ 306,456	$ 1,282,389	$ 2,552,619	$ 5,021,076
Working capital	$ 1,062,741		1,062,741
Total expected expenditure for operating expenses and investment activity			$ 1,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities excluded from computation of earnings per share	6,144,212	7,681,713
Options [Member]
Antidilutive securities excluded from computation of earnings per share	5,997,544	6,546,710
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	146,668	1,135,003

XML 36 R25.htm IDEA: XBRL DOCUMENT

Operating Lease (Details Narrative) - USD ($)	9 Months Ended
Operating Lease (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Operating lease remaining lease term	12 months
Lease expenses	$ 100,789	$ 93,845
Operating Lease Agreement [Member]
Lease expenses	$ 45,970	$ 139,218

XML 37 R26.htm IDEA: XBRL DOCUMENT

Operating Lease - Schedule of Lease Expenses (Details)	9 Months Ended
Operating Lease - Schedule of Lease Expenses (Details)	Dec. 31, 2020 USD ($)
Leases [Abstract]
Operating lease cost (included in general and administrative expenses in the Company's unaudited condensed consolidated statement of operations)	$ 111,657
Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2020
Weighted average remaining lease term - operating leases (in years)	2 months 12 days
Average discount rate - operating leases	4.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Operating Lease - Schedule of Supplement Related to Lease (Details) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Leases [Abstract]
Operating Leases: Long-term right-of-use asset	$ 22,817	$ 123,606
Operating Leases: Short-term operating lease liability	23,194	$ 125,679
Operating Leases: Total operating lease liabilities	$ 23,194

XML 39 R28.htm IDEA: XBRL DOCUMENT

Operating Lease - Schedule of Maturities of Lease Liabilities (Details)	Dec. 31, 2020 USD ($)
Leases [Abstract]
2021 (remaining 2 months)	$ 23,310
Total lease payments	23,310
Less: Imputed interest/present value discount	(116)
Present value of lease liabilities	$ 23,194

XML 40 R29.htm IDEA: XBRL DOCUMENT

Gain on Extinguishment of Note Payable (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 21, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	May 06, 2020
Gain on extinguishment of loan		$ 97,516		$ 97,516
Paycheck Protection Program [Member]
Forgiveness of loan	$ 97,516
Accrued interest	$ 528
Paycheck Protection Program [Member] \| U.S. Bank [Member]
Loans payable						$ 96,988
Debt instrument, interest rate						1.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Gain on Settlement (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Gain on Settlement (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2020
Gain On Settlement Details Narrative Abstract
Due to vendor		$ 1,100,000		$ 1,100,000
Accounts payable to vendor					$ 612,405
Gain on settlement of outstanding invoices			$ 612,405
Payment from vendor			450,000
Gain on settlement	$ 1,062,405		$ 1,062,405

XML 42 R31.htm IDEA: XBRL DOCUMENT

Advance (Details Narrative) - USD ($)	Dec. 31, 2020	Mar. 31, 2020	Jul. 31, 2018
Receivables [Abstract]
Advance	$ 296,653	$ 296,653	$ 250,000
Other current liabilities			$ 46,653

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stock Options (Details Narrative) - USD ($)	9 Months Ended
Stock Options (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 349,546	$ 492,554
Unamortized cost of outstanding stock-based awards	$ 160,000
Weighted average remaining vesting period	1 year
Outstanding stock options	5,997,544		6,556,710

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock Options - Summary of Stock Option Activity (Details)	9 Months Ended
	Dec. 31, 2020 $ / shares shares
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance Outstanding \| shares	6,556,710
Shares, Granted \| shares
Shares, Exercised \| shares
Shares, Expired \| shares	(32,500)
Shares, Cancelled \| shares	(526,666)
Shares Outstanding, Ending Balance \| shares	5,997,544
Shares, Balance Exercisable \| shares	4,622,544
Weighted Average Exercise Price, Outstanding Beginning Balance \| $ / shares	$ 0.89
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares	2.17
Weighted Average Exercise Price, Cancelled \| $ / shares	1.42
Weighted Average Exercise Price, Outstanding Ending Balance \| $ / shares	0.91
Weighted Average Exercise Price, Balance Exercisable \| $ / shares	$ 0.87

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	5,997,544	6,556,710
Weighted Average Grant-date Stock Price, Options Outstanding
Number of Options, Options Exercisable	4,622,544
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	750,000
Weighted Average Exercise Price, Options Outstanding	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30
Number of Options, Options Exercisable	375,000
Weighted Average Exercise Price, Options Exercisable	$ 0.30
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.30
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	2,000,000
Weighted Average Exercise Price, Options Outstanding	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35
Number of Options, Options Exercisable	1,000,000
Weighted Average Exercise Price, Options Exercisable	$ 0.35
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.35
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	1,664,542
Weighted Average Exercise Price, Options Outstanding	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.50
Number of Options, Options Exercisable	1,664,542
Weighted Average Exercise Price, Options Exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.50
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	128,000
Weighted Average Exercise Price, Options Outstanding	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.96
Number of Options, Options Exercisable	128,000
Weighted Average Exercise Price, Options Exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.96
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	130,000
Weighted Average Exercise Price, Options Outstanding	$ 1.00
Weighted Average Grant-date Stock Price, Options Outstanding	$ 10.00
Number of Options, Options Exercisable	130,000
Weighted Average Exercise Price, Options Exercisable	$ 1.00
Weighted Average Grant-date Stock Price, Options Exercisable	$ 10.00
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	500,834
Number of Options, Options Exercisable	500,834
Stock Options Six [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding	1.50
Weighted Average Exercise Price, Options Exercisable	1.50
Weighted Average Grant-date Stock Price, Options Exercisable	1.50
Stock Options Six [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	1.95
Weighted Average Grant-date Stock Price, Options Outstanding	1.95
Weighted Average Exercise Price, Options Exercisable	1.95
Weighted Average Grant-date Stock Price, Options Exercisable	$ 1.95
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	657,500
Number of Options, Options Exercisable	657,500
Stock Options Seven [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 2.00
Weighted Average Grant-date Stock Price, Options Outstanding	2.00
Weighted Average Exercise Price, Options Exercisable	2.00
Weighted Average Grant-date Stock Price, Options Exercisable	2.00
Stock Options Seven [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2.79
Weighted Average Grant-date Stock Price, Options Outstanding	2.79
Weighted Average Exercise Price, Options Exercisable	2.79
Weighted Average Grant-date Stock Price, Options Exercisable	$ 2.79
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	123,334
Number of Options, Options Exercisable	123,334
Stock Options Eight [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding	3.10
Weighted Average Exercise Price, Options Exercisable	3.10
Weighted Average Grant-date Stock Price, Options Exercisable	3.10
Stock Options Eight [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.80
Weighted Average Grant-date Stock Price, Options Outstanding	3.80
Weighted Average Exercise Price, Options Exercisable	3.80
Weighted Average Grant-date Stock Price, Options Exercisable	$ 3.80
Stock Options Nine[Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	43,334
Number of Options, Options Exercisable	43,334
Stock Options Nine[Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 4.00
Weighted Average Grant-date Stock Price, Options Outstanding	4.00
Weighted Average Exercise Price, Options Exercisable	4.00
Weighted Average Grant-date Stock Price, Options Exercisable	4.00
Stock Options Nine[Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4.70
Weighted Average Grant-date Stock Price, Options Outstanding	4.70
Weighted Average Exercise Price, Options Exercisable	4.70
Weighted Average Grant-date Stock Price, Options Exercisable	$ 4.70

XML 46 R35.htm IDEA: XBRL DOCUMENT

Warrants (Details Narrative)	Dec. 31, 2020 shares
Warrants [Member]
Outstanding warrants	146,668

XML 47 R36.htm IDEA: XBRL DOCUMENT

Warrants - Summary of Warrants Activity (Details) - Warrants [Member]	9 Months Ended
	Dec. 31, 2020 $ / shares shares
Number of Shares, Warrants Outstanding, Beginning Balance \| shares	1,135,003
Number of Shares, Warrants Granted \| shares
Number of Shares, Warrants Exercised \| shares
Number of Shares, Warrants Expired \| shares	(988,335)
Number of Shares, Warrants Outstanding and Exercisable Ending Balance \| shares	146,668
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance \| $ / shares	$ 2.19
Weighted Average Exercise Price, Warrants Outstanding, Granted \| $ / shares
Weighted Average Exercise Price, Warrants Outstanding, Exercised \| $ / shares
Weighted Average Exercise Price, Warrants Outstanding, Expired \| $ / shares	2.10
Weighted Average Exercise Price, Warrants Outstanding, Outstanding and Exercisable, Ending Balance \| $ / shares	$ 3.00

XML 48 R37.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Revenue				$ 44,698
Cost of sales				143,232
Research and development				4,361
General and administrative		48,769		611,932
Loss from discontinued operations		$ (48,769)		$ (714,827)

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	Aug. 19, 2016 shares
Common Stock One [Member]
Common stock issuable upon exercise of certain warrants	2,650,000
Common Stock Two [Member]
Common stock issuable upon exercise of certain warrants	7,950,000

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 87 243 1 false 22 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://vitality.bio/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://vitality.bio/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://vitality.bio/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://vitality.bio/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes In Stockholders' Equity (Unaudited) Sheet http://vitality.bio/role/StatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes In Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://vitality.bio/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://vitality.bio/role/StatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 7 false false R8.htm 00000008 - Disclosure - Business Operations and Summary of Significant Accounting Policies Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies Business Operations and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Operating Lease Sheet http://vitality.bio/role/OperatingLease Operating Lease Notes 9 false false R10.htm 00000010 - Disclosure - Gain on Extinguishment of Note Payable Sheet http://vitality.bio/role/GainOnExtinguishmentOfNotePayable Gain on Extinguishment of Note Payable Notes 10 false false R11.htm 00000011 - Disclosure - Gain on Settlement Sheet http://vitality.bio/role/GainOnSettlement Gain on Settlement Notes 11 false false R12.htm 00000012 - Disclosure - Advance Sheet http://vitality.bio/role/Advance Advance Notes 12 false false R13.htm 00000013 - Disclosure - Stock Options Sheet http://vitality.bio/role/StockOptions Stock Options Notes 13 false false R14.htm 00000014 - Disclosure - Warrants Sheet http://vitality.bio/role/Warrants Warrants Notes 14 false false R15.htm 00000015 - Disclosure - Discontinued Operations Sheet http://vitality.bio/role/DiscontinuedOperations Discontinued Operations Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://vitality.bio/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Business Operations and Summary of Significant Accounting Policies (Policies) Policies http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables Business Operations and Summary of Significant Accounting Policies (Tables) Tables http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Operating Lease (Tables) Sheet http://vitality.bio/role/OperatingLeaseTables Operating Lease (Tables) Tables http://vitality.bio/role/OperatingLease 19 false false R20.htm 00000020 - Disclosure - Stock Options (Tables) Sheet http://vitality.bio/role/StockOptionsTables Stock Options (Tables) Tables http://vitality.bio/role/StockOptions 20 false false R21.htm 00000021 - Disclosure - Warrants (Tables) Sheet http://vitality.bio/role/WarrantsTables Warrants (Tables) Tables http://vitality.bio/role/Warrants 21 false false R22.htm 00000022 - Disclosure - Discontinued Operations (Tables) Sheet http://vitality.bio/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://vitality.bio/role/DiscontinuedOperations 22 false false R23.htm 00000023 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Business Operations and Summary of Significant Accounting Policies (Details Narrative) Details http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 24 false false R25.htm 00000025 - Disclosure - Operating Lease (Details Narrative) Sheet http://vitality.bio/role/OperatingLeaseDetailsNarrative Operating Lease (Details Narrative) Details http://vitality.bio/role/OperatingLeaseTables 25 false false R26.htm 00000026 - Disclosure - Operating Lease - Schedule of Lease Expenses (Details) Sheet http://vitality.bio/role/OperatingLease-ScheduleOfLeaseExpensesDetails Operating Lease - Schedule of Lease Expenses (Details) Details 26 false false R27.htm 00000027 - Disclosure - Operating Lease - Schedule of Supplement Related to Lease (Details) Sheet http://vitality.bio/role/OperatingLease-ScheduleOfSupplementRelatedToLeaseDetails Operating Lease - Schedule of Supplement Related to Lease (Details) Details 27 false false R28.htm 00000028 - Disclosure - Operating Lease - Schedule of Maturities of Lease Liabilities (Details) Sheet http://vitality.bio/role/OperatingLease-ScheduleOfMaturitiesOfLeaseLiabilitiesDetails Operating Lease - Schedule of Maturities of Lease Liabilities (Details) Details 28 false false R29.htm 00000029 - Disclosure - Gain on Extinguishment of Note Payable (Details Narrative) Sheet http://vitality.bio/role/GainOnExtinguishmentOfNotePayableDetailsNarrative Gain on Extinguishment of Note Payable (Details Narrative) Details http://vitality.bio/role/GainOnExtinguishmentOfNotePayable 29 false false R30.htm 00000030 - Disclosure - Gain on Settlement (Details Narrative) Sheet http://vitality.bio/role/GainOnSettlementDetailsNarrative Gain on Settlement (Details Narrative) Details http://vitality.bio/role/GainOnSettlement 30 false false R31.htm 00000031 - Disclosure - Advance (Details Narrative) Sheet http://vitality.bio/role/AdvanceDetailsNarrative Advance (Details Narrative) Details http://vitality.bio/role/Advance 31 false false R32.htm 00000032 - Disclosure - Stock Options (Details Narrative) Sheet http://vitality.bio/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://vitality.bio/role/StockOptionsTables 32 false false R33.htm 00000033 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) Sheet http://vitality.bio/role/StockOptions-SummaryOfStockOptionActivityDetails Stock Options - Summary of Stock Option Activity (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Sheet http://vitality.bio/role/StockOptions-ScheduleOfStockOptionsOutstandingAndExercisableDetails Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Details 34 false false R35.htm 00000035 - Disclosure - Warrants (Details Narrative) Sheet http://vitality.bio/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://vitality.bio/role/WarrantsTables 35 false false R36.htm 00000036 - Disclosure - Warrants - Summary of Warrants Activity (Details) Sheet http://vitality.bio/role/Warrants-SummaryOfWarrantsActivityDetails Warrants - Summary of Warrants Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) Sheet http://vitality.bio/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationsForSummitHealthcareDetails Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) Details 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://vitality.bio/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://vitality.bio/role/CommitmentsAndContingencies 38 false false All Reports Book All Reports vbio-20201231.xml vbio-20201231.xsd vbio-20201231_cal.xml vbio-20201231_def.xml vbio-20201231_lab.xml vbio-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 55 0001493152-21-002062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-002062-xbrl.zip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end